- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03986905
The Prevention and Treatment of Nausea Associated With Motion Sickness
December 2, 2019 updated by: Repurposed Therapeutics, Inc.
A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness
This single-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety and efficacy of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
The study will be conducted aboard an ocean going vessel to obtain data in a real world environment.
The study will have three arms: DPI-386 nasal gel, placebo nasal gel, and TDS patch (1.5 mg/72 hours), the current standard of care for the treatment of motion sickness.
The study will include 100 subjects per arm, for a total of 300 subjects (n=300).
Multiple voyages with the same vessel will be used until the required enrollment is completed.
A double dummy design will be used to mask the treatment assignment.
All subjects will receive both a patch and nasal gel randomized to one of the following three arms: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, and placebo nasal gel + TDS patch.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigational product will be administered using a delivery device comprised of: (a) a vial prefilled with DPI-386 Nasal Gel or placebo nasal gel, and (b) a nasal gel pump attached to the vial during the manufacturing process.
Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr as the active ingredient along with the excipients sodium citrate, citric acid, sodium metabisulfite, glycerin, benzalkonium chloride, polyvinyl alcohol and purified water.
The DPI 386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.12 g dose, with each dose therefore described as "0.2 mg / 0.12 g".
The placebo nasal gel product is the same but does not contain scopolamine HBr.
Each vial of DPI 386 Nasal Gel or placebo nasal gel is a multi-dose product, sufficient for three days of dosing (two doses per day).
Each pumping action is designed to deliver a single 0.12 g dose.
Each vial/delivery device must be primed by the subject prior to first dose delivery for that vial.
Each time a new bottle is used, it needs to be initially primed with 5 actuations.
The 6th actuation is the first dose and subsequent actuations are doses 2-6 of that bottle.
No re-priming is needed at all.
Subjects will be trained in priming by research staff, and all priming will be performed under supervision by the research staff.
All subjects will self-administer the nasal gel twice daily over the three day treatment period, with no more than two doses every 24 hours, unless a third dose is deemed necessary by the PI or qualified designee, and the two daily doses separated by a minimum of six hours ± 15 minutes
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90806
- Collaborative Neuroscience Network, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 59 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of a signed and dated Informed Consent Form (ICF).
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, aged 18 to 59 (inclusive).
- At least minimally susceptible to provocative motion as evidenced by a minimum score of 3.0 on the Motion Sickness Susceptibility Questionnaire (MSSQ).
- In good general health as evidenced by medical history with no recent history or current diagnosis of uncontrolled clinical problems as assessed by the Principal Investigator (PI) or qualified designee.
- Ability to take intranasal medication and willingness to adhere to the study schedule and time constraints.
- For females of child-bearing potential: willingness to provide a urine sample for the hCG pregnancy test. The test must be negative within seven days of Treatment Day 1.
- Agreement to adhere to the following lifestyle compliance considerations:
- Refrain from consumption of grapefruit and any substance containing grapefruit for seven days prior to, during, and for seven days after the three Treatment Days.
- Abstain from alcohol for 24 hours prior to first dose of study medication and during the three Treatment Days.
Exclusion Criteria:
- Pregnancy, lactation, or positive urine pregnancy test within seven days of Treatment Day 1.
- Known allergic reactions to scopolamine or other anticholinergics.
- Currently prescribed any of the following medication types and used within the specified washout periods below:
- any form of scopolamine (including Transderm Scop®) (washout 5 days)
- belladonna alkaloids (washout 2 weeks),
- antihistamines (including meclizine) (washout 2 weeks),
- tricyclic antidepressants (washout 2 weeks),
- muscle relaxants (washout 4 days) and
- nasal decongestants (washout 4 days)
- Hospitalization or significant surgery requiring hospital admittance within the past six months.
- Treatment with another investigational drug or other intervention within the past 30 days.
- Having donated blood or plasma or suffered significant blood loss within the past 30 days.
Having any of the following medical conditions within the last two years or if any of the following medical conditions were experienced more than two years ago and are deemed clinically significant by the PI or qualified designee:
- Significant gastrointestinal disorder, asthma, or seizure disorders.
- History of vestibular disorders.
- History of narrow-angle glaucoma.
- History of urinary retention problems.
- History of alcohol or drug abuse.
- Nasal, nasal sinus, or nasal mucosa surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Scopolamine Nasal Gel
DPI-386 Nasal Gel + placebo patch
|
All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
Other Names:
placebo nasal gel + placebo patch
Other Names:
|
Placebo Comparator: Placebo
placebo nasal gel + placebo patch
|
placebo nasal gel + placebo patch
Other Names:
|
Active Comparator: TDS Patch
placebo nasal gel + TDS patch
|
All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
Other Names:
placebo nasal gel + placebo patch
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The efficacy endpoint is incidence of subjects who developed motion sickness and request further treatment during an 8 hour voyage
Time Frame: During three consecutive days
|
The efficacy endpoint is incidence of subjects who developed motion sickness and request further treatment with Rescue medication during an 8 hour voyage on Treatment Day 1.
|
During three consecutive days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Dave Helton, Repurposed Therapeutics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2019
Primary Completion (Actual)
May 19, 2019
Study Completion (Actual)
June 19, 2019
Study Registration Dates
First Submitted
June 6, 2019
First Submitted That Met QC Criteria
June 13, 2019
First Posted (Actual)
June 14, 2019
Study Record Updates
Last Update Posted (Actual)
December 3, 2019
Last Update Submitted That Met QC Criteria
December 2, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Motion Sickness
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Antiemetics
- Gastrointestinal Agents
- Adjuvants, Anesthesia
- Mydriatics
- Scopolamine
- Butylscopolammonium Bromide
Other Study ID Numbers
- DPI-386-MS-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
In publication and CSR.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motion Sickness
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness, Space | Motion Simulation | Parabolic FlightUnited States
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Faisal_Karmali@MEEI.HARVARD.EDUMassachusetts Institute of Technology; National Space Biomedical Research InstituteCompleted
-
Naval Aeromedical Research Unit, DaytonUnknownPrevention of Nausea Associated With Motion Sickness | Treatment of Nausea Associated With Motion SicknessUnited States
-
Wingate Institute of NeurogastroenterologyCompletedVisually Induced Motion Sickness in Healthy VolunteersUnited Kingdom
-
University Hospital, CaenCompleted
-
United States Army Aeromedical Research LaboratoryAlabama College of Osteopathic Medicine; Department of Aviation Medicine, U...CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Dartmouth-Hitchcock Medical CenterRecruiting
-
Vanda PharmaceuticalsRecruitingMotion SicknessUnited States
Clinical Trials on Scopolamine Nasal Gel
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Repurposed Therapeutics, Inc.Defender Pharmaceuticals, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Millennium Pharmaceuticals, Inc.CompletedMyelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, ChronicUnited States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
-
Acerus Pharmaceuticals CorporationCompletedFemale Sexual DysfunctionUnited States
-
Destiny Pharma PlcCompletedStaphylococcus Aureus InfectionUnited Kingdom
-
VA Office of Research and DevelopmentRecruiting
-
Repurposed Therapeutics, Inc.CompletedMotion SicknessUnited States